Literature DB >> 7799086

Indium-111 activity concentration in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-1-octreotide.

E Forssell-Aronsson1, M Fjälling, O Nilsson, L E Tisell, B Wängberg, H Ahlman.   

Abstract

METHODS: Indium-111 activity concentrations in human tumor and normal tissue samples were determined at 24, 48 and 120 hr after i.v. injection of 111In-DTPA-D-Phe-1-octreotide. Fourteen patients were included in the study. Seven patients had medullary thyroid carcinoma, four had midgut carcinoid tumors, two had endocrine pancreatic tumors and one had chronic pancreatitis.
RESULTS: For midgut carcinoids, the tumor-to-blood ratio was 51:220, for medullary thyroid carcinoma 4:39, and for two endocrine pancreatic tumors 6 and 1500. Tumor-to-muscle ratios varied between 1 and 1200 and tumor-to-fat between 2 and 1500 depending on tumor type.
CONCLUSION: The sometimes extremely high tumor-to-normal tissue ratios present the possibility for use of radiolabeled octreotide for radiation therapy of somatostatin receptor positive tumors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7799086

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  11 in total

1.  Toward the Design of MR Agents for Imaging β-Cell Function.

Authors:  Mark Woods; Shanrong Zhang; A Dean Sherry
Journal:  Curr Med Chem Immunol Endocr Metab Agents       Date:  2004-12

2.  Early massive accumulation of In-111 pentetreotide in a metastatic liver tumor of islet cell carcinoma.

Authors:  E Tsukamoto; K Kanegae; K Itoh; S Okushiba; K Ohno; H Katoh; N Tamaki
Journal:  Ann Nucl Med       Date:  1996-08       Impact factor: 2.668

3.  A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake.

Authors:  L Kölby; P Bernhardt; H Ahlman; B Wängberg; V Johanson; A Wigander; E Forssell-Aronsson; S Karlsson; B Ahrén; G Stenman; O Nilsson
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

Review 4.  Therapeutic radionuclides in nuclear medicine: current and future prospects.

Authors:  Chai-Hong Yeong; Mu-hua Cheng; Kwan-Hoong Ng
Journal:  J Zhejiang Univ Sci B       Date:  2014-10       Impact factor: 3.066

5.  [177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney.

Authors:  Christina Swärd; Peter Bernhardt; Håkan Ahlman; Bo Wängberg; Eva Forssell-Aronsson; Maria Larsson; Johanna Svensson; Rauni Rossi-Norrlund; Lars Kölby
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

6.  Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.

Authors:  O Nilsson; L Kölby; B Wängberg; A Wigander; H Billig; L William-Olsson; M Fjälling; E Forssell-Aronsson; H Ahlman
Journal:  Br J Cancer       Date:  1998-02       Impact factor: 7.640

7.  Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour.

Authors:  L Kölby; P Bernhardt; V Johanson; A Schmitt; H Ahlman; E Forssell-Aronsson; H Mäcke; O Nilsson
Journal:  Br J Cancer       Date:  2005-11-14       Impact factor: 7.640

8.  Expression of somatostatin receptors in oncocytic (Hürthle cell) neoplasia of the thyroid.

Authors:  L E Tisell; H Ahlman; B Wängberg; L Kölby; M Fjälling; E Forssell-Aronsson; J Mölne; O Nilsson
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

9.  Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phe1-octreotide.

Authors:  B Wangberg; E Forssell-Aronsson; L E Tisell; O Nilsson; M Fjalling; H Ahlman
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

10.  Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters.

Authors:  L Kölby; P Bernhardt; A-M Levin-Jakobsen; V Johanson; B Wängberg; H Ahlman; E Forssell-Aronsson; O Nilsson
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.